SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update.

IF 7.5 1区医学 Q1 CLINICAL NEUROLOGY

Neurology® Neuroimmunology & Neuroinflammation Pub Date : 2025-05-01 Epub Date: 2025-04-25 DOI:10.1212/NXI.0000000000200393

Tobias Monschein, Tobias Zrzavy, Paulus S Rommer, Sven G Meuth, Andrew Chan, Thomas Berger, Hans-Peter Hartung

{"title":"SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update.","authors":"Tobias Monschein, Tobias Zrzavy, Paulus S Rommer, Sven G Meuth, Andrew Chan, Thomas Berger, Hans-Peter Hartung","doi":"10.1212/NXI.0000000000200393","DOIUrl":null,"url":null,"abstract":"The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.1-3 Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.4 In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.","PeriodicalId":19472,"journal":{"name":"Neurology® Neuroimmunology & Neuroinflammation","volume":"12 3","pages":"e200393"},"PeriodicalIF":7.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051395/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology® Neuroimmunology & Neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXI.0000000000200393","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.^1-3 Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.⁴ In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.

Abstract Image

查看原文本刊更多论文

SARS-CoV-2疫苗与多发性硬化症：最新进展

由严重急性呼吸系统综合征冠状病毒2 （SARS-CoV-2）引起的高传染性人兽共患病冠状病毒病2019 （COVID-19）于2020年3月11日被世界卫生组织宣布为大流行，截至2019年11月10日，已导致全球卫生危机，全球确诊病例近7.77亿，死亡人数超过700万。随着时间的推移，出现了各种变体，欧米克隆及其子公司在过去3年中主导了世界此外，越来越多的证据表明，SARS-CoV-2疫苗的免疫反应，特别是对接受疾病改善疗法的多发性硬化症（MS）患者。因此，通过这篇综述，我们旨在提供关于MS和SARS-CoV-2疫苗的最新概述和临床实践建议，包括有效性和安全性、SARS-CoV-2变体、疫苗犹豫性和各自疾病修饰疗法治疗下的免疫反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology® Neuroimmunology & Neuroinflammation Neuroscience-Neurology

CiteScore

15.60

自引率

2.30%

发文量

219

审稿时长

8 weeks

期刊介绍： Neurology Neuroimmunology & Neuroinflammation is an official journal of the American Academy of Neurology. Neurology: Neuroimmunology & Neuroinflammation will be the premier peer-reviewed journal in neuroimmunology and neuroinflammation. This journal publishes rigorously peer-reviewed open-access reports of original research and in-depth reviews of topics in neuroimmunology & neuroinflammation, affecting the full range of neurologic diseases including (but not limited to) Alzheimer's disease, Parkinson's disease, ALS, tauopathy, and stroke; multiple sclerosis and NMO; inflammatory peripheral nerve and muscle disease, Guillain-Barré and myasthenia gravis; nervous system infection; paraneoplastic syndromes, noninfectious encephalitides and other antibody-mediated disorders; and psychiatric and neurodevelopmental disorders. Clinical trials, instructive case reports, and small case series will also be featured.